Online inquiry

IVTScrip™ mRNA-Human ASB1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK25093MR)

This product GTTS-WK25093MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ASB1 protein. This product can be used in Natural killer T (NKT) cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001040445.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 51665
UniProt ID Q9Y576
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ASB1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK25093MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK25081MR IVTScrip™ mRNA-Human ARRDC3-AS1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARRDC3-AS1
GTTS-WK11100MR IVTScrip™ mRNA-Human Aggrecan, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Aggrecan
GTTS-WK21501MR IVTScrip™ mRNA-Human ANKRD13D, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANKRD13D
GTTS-WK17638MR IVTScrip™ mRNA-Human ANKS3, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANKS3
GTTS-WK28588MR IVTScrip™ mRNA-Human ARHGAP23, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARHGAP23
GTTS-WK24756MR IVTScrip™ mRNA-Human ARMC5, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARMC5
GTTS-WK18929MR IVTScrip™ mRNA-Human AIDA, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AIDA
GTTS-WK22960MR IVTScrip™ mRNA-Human ARMCX3, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ARMCX3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW